Skip to content
Screener

Kyverna Therapeutics, Inc. KYTX Q3 2025 earnings

Reported November 12, 2025 · Before market open

EPS-$0.85Beat by $0.12
EPS estimate-$0.97

Next report

Nov 11, 2026 (in 2 months)
EPS estimate-$0.68

Financials

Q3 2025

Income statement

See full
Operating income-$38.7M+0.1%
Net income-$36.8M-6.7%
EPS (diluted)-$0.85-6.2%

Balance sheet

See full
Cash & equivalents$34.2M-67.4%
Total debt$5.0M-50.1%
Total equity$151.9M-49.8%
Total assets$187.2M-44.8%

Cash flow

See full
Operating cash flow-$43.3M-57.6%
CapEx$2.0K-98.0%
Free cash flow-$43.3M-57.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$259.47M+23.0%
Enterprise value$230.33M+97.9%

Returns & leverage

See full
Return on equity-70.8%—
Debt / equity0×0.0×
Current ratio5.2×-5.3×

FAQ

When did Kyverna Therapeutics, Inc. report Q3 2025 earnings?
Kyverna Therapeutics, Inc. (KYTX) reported Q3 2025 earnings on November 12, 2025 before market open.
What were Kyverna Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Kyverna Therapeutics, Inc. reported eps of $-0.85 for Q3 2025.
Did Kyverna Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.97 by $0.12.
How did Kyverna Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 6.2% from $-0.80.
Where can I find Kyverna Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-277569) and the 10-Q periodic report (0001193125-25-277584) directly on SEC EDGAR. The filing index links above go to sec.gov.